ENTrIA (Engineered Treg for Inflammation and Autoimmunity) is the second TxCell proprietary cellular immunotherapy product platform.

ENTrIA is composed of Chimeric Antigen Receptor engineered Regulatory T cells (CAR-Treg)

The antigen specificity comes from the CAR receptor as shown below.

After their isolation from the blood of patients, Treg cells are genetically modified by transduction with Chimeric Antigen Receptors (CAR). The CAR introduced into Treg cells is designed to allow Treg cell activation and immuno-modulation through in vivo recognition of a protein present in inflamed areas in patients suffering from autoimmune and chronic inflammatory diseases.

TxCell has intensified the research efforts on its second technology platform, ENTrIA, composed of engineered regulatory T cells (CAR-Treg). These efforts have led to the initiation of more than 10 new CAR development programs. Initially, TxCell is focusing its resources on four to five CAR-Treg programs targeting notably lupus nephritis, bullous pemphigoid, multiple sclerosis and transplantation.

TxCell’s objectives are: firstly, to generate regularly additional preclinical proof-of-concept data and, secondly, to start at least one first-in-man clinical study before the end of 2018. A number of these programs are being developed through collaboration agreements with leading international academic laboratories, such as the University of British Columbia (UBC) in Canada, Ospedale San Raffaele (OSR) in Italy and the Lübeck Institute of Experimental Dermatology (LIED) in Germany.